Elanco Animal Health Incorporated Impairment of Intangible Assets (Excluding Goodwill)
Elanco Animal Health Incorporated (ELAN) reported Impairment of Intangible Assets (Excluding Goodwill) of $56.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2025-02-25
- Elanco Animal Health Incorporated impairment of intangible assets (excluding goodwill) for the quarter ending 2018-12-31 was $2.60M.
- Elanco Animal Health Incorporated impairment of intangible assets (excluding goodwill) for fiscal 2024 was $56.00M, a 833.33% increase from fiscal 2023.
- Elanco Animal Health Incorporated impairment of intangible assets (excluding goodwill) for fiscal 2023 was $6.00M, a 89.83% decline from fiscal 2022.
- Elanco Animal Health Incorporated impairment of intangible assets (excluding goodwill) for fiscal 2022 was $59.00M, a 7.27% increase from fiscal 2021.
- Elanco Animal Health Incorporated impairment of intangible assets (excluding goodwill) for fiscal 2021 was $55.00M, a 223.53% increase from fiscal 2020.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | $56.00M 10-K · filed 2025-02-25 | |||
| 2023-12-31 | $6.00M 10-K · filed 2025-02-25 | |||
| 2022-12-31 | $59.00M 10-K · filed 2025-02-25 | $60.00M 10-K · filed 2023-03-01 | ||
| 2021-12-31 | $55.00M 10-K · filed 2024-02-26 | $66.00M 10-K · filed 2022-02-28 | ||
| 2020-12-31 | $17.00M 10-K · filed 2023-03-01 | $17.50M 10-K · filed 2021-03-01 | ||
| 2019-12-31 | $11.00M 10-K · filed 2022-02-28 | $11.40M 10-K · filed 2020-02-28 | ||
| 2018-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $22.50M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $19.90M 10-Q · filed 2018-11-08 | |||
| 2017-12-31 | $94.50M 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $14.00M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |